Patents Assigned to Codagenix, Inc.
  • Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
    Patent number: 12054519
    Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: August 6, 2024
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, Codagenix, Inc.
    Inventors: Cyril Le Nouen, Ursula J. Buchholz, Peter L. Collins, Steffen Mueller
  • Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
    Patent number: 11390651
    Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: July 19, 2022
    Assignees: The USA, Secretary, DHHS, Codagenix, Inc.
    Inventors: Cyril Lenouen, Ursula J. Buchholz, Peter L. Collins, Steffen Mueller
  • Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
    Patent number: 10808012
    Abstract: Reported herein are presumptively de-attenuating mutations that are useful, either individually or in combinations that may include other known mutations, in producing recombinant strains of human respiratory syncytial virus (RSV) exhibiting attenuation phenotypes. Also described herein is a novel RSV construct, Min_L-NPM2-1(N88K)L, which exhibits an attenuated phenotype, is stable and is as immunogenic as wild type RSV. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Exemplary vaccine candidates are described. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: October 20, 2020
    Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, Codagenix, Inc.
    Inventors: Cyril Lenouen, Ursula J. Buchholz, Peter L. Collins, Steffen Mueller